Kintara Therapeutics, Inc. Price Today
Kintara Therapeutics, Inc.
KTRA
Healthcare
$7.23M
💰
Market Cap
0
💸
Price to Earnings
$-9.3
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
4 |
Strong Buy |
2 |
Hold |
2 |
Sell |
0 |
Strong Sell |
0 |
KTRA Price Forecast Target
4.1 👉 14.0 +238%
KTRA EPS Forecast
-9.3 👉 0.1 +-101%
Financials
Profit Margin
0 %
Revenue Growth
0 %
Dividend
$ 0
Held Percent
4.2% - Insiders
3.3% - Institutions
92.5% - Public
Major Fund Holders
-
💰 $
-
💰 $
-
💰 $
-
💰 $
-
💰 $
Stock Ideas
Nancy Pelosi Portfolio
Nancy Pelosi is the Speaker of the United States House of Representatives and a savvy investor. Her personal portfolio is heavily weighted towards large-cap tech stocks, such as Apple and Microsoft. She also owns shares in several consumer staples a…
Bill Ackman Portfolio
Bill Ackman, a renowned investor, has established himself as a long-term value investor with a keen eye for short-term price fluctuations. His expertise lies in special situations investments, and his Pershing Square portfolio reflects a highly conc…
Larry Robbins Portfolio
Larry Robbins is a successful hedge fund manager who founded Glenview Capital in 2001 after working as a trader at Omega Advisors. His portfolio strategy has led to impressive returns, with Glenview Capital returning 301% after fees and expenses bet…
Ray Dalio Portfolio
Ray Dalio, a visionary entrepreneur and investment strategist, laid the foundation of Bridgewater with a clear vision in mind. His relentless pursuit of excellence, coupled with an unwavering commitment to innovation, has propelled Bridgewater to be…📮FAQ
Some Frequently Asked Questions.
The Kintara Therapeutics, Inc. industry is Biotechnology
The Kintara Therapeutics, Inc. sector is Healthcare
The Kintara Therapeutics, Inc. forecasted predicted Price to Earnings PE ratio is 82.8
The Kintara Therapeutics, Inc. Price to Earnings PE ratio is 0
The Market Capitalization of Kintara Therapeutics, Inc. is $7.23M
There are total of 1734917 float shares with 3.3% held by Institutions and 4.2% held by insiders
The MKintara Therapeutics, Inc. forecasted Earnings per Share EPS is $0.1
The Kintara Therapeutics, Inc. Earnings per Share EPS is -9.3
The Kintara Therapeutics, Inc. company has $0 gross profits with 0 profit margins
The Kintara Therapeutics, Inc. Earnings Growth is 0% with 0% quarterly earnings growth
The Kintara Therapeutics, Inc. Revenue is $0 with 0 revenue growth
The price target for Kintara Therapeutics, Inc. stock is $14.0 for the high target and $14.0 for the low target
The consensus analyst recommendations for Kintara Therapeutics, Inc. is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Kintara Therapeutics, Inc. is Buy, with the following breakdown:
- Buy: 4
- Strong Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
The Beta of Kintara Therapeutics, Inc. is 1.0
The dividend of Kintara Therapeutics, Inc. is $0
The dividend yield of Kintara Therapeutics, Inc. is 0%
The biggest institutional and mutual fund holders of Kintara Therapeutics, Inc. stock are
The Kintara Therapeutics, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0